Assertio Holdings, Inc. (ASRT)

In Q3 2025, Assertio reported financial results, beating analysts' consensus estimates for both EPS and revenue, with Rolvedon net product sales increasing from the prior-year quarter. Assertio completed a reverse stock-split in December 2025. Assertio regained compliance with all applicable Nasdaq listing requirements in January 2026. Wall Street Zen upgraded Assertio to a buy rating in November 2025. Zacks Research raised Assertio from a hold to a strong-buy rating in December 2025. HC Wainwright reaffirmed a buy rating and increased its price objective to $35.00 in January 2026. Fintel reported a price target increase to $38.19 in January 2026. Assertio Holdings, Inc.'s stock price rose 3.9% on February 2, 2026.

Information regarding the specific demand seasonality for Assertio Holdings, Inc.'s products and services is not publicly available in the provided search results.

Assertio Holdings, Inc. is a pharmaceutical company focused on developing and commercializing differentiated products to address patient needs in neurology, orphan and specialty medicines, oncology, hospital, and pain and inflammation. The company operates within the Healthcare sector, specifically in the Biotechnology: Pharmaceutical Preparations industry. Assertio's major products include Gralise, CAMBIA, Zipsor, INDOCIN, SPRIX, Otrexup, Sympazan and ROLVEDON.

Assertio Holdings, Inc. primarily provides its various pharmaceutical products to patients in the United States.

Assertio Holdings, Inc. has faced a securities fraud class action lawsuit filed in early 2024, alleging materially false and misleading statements regarding its business, operations, and prospects. The complaint claims Assertio misrepresented and concealed that its reliance on Indocin products for net income was unsustainable due to generic competition, and that the Spectrum acquisition was less valuable than represented. This lawsuit is ongoing, with a motion to dismiss the amended complaint filed in August 2024 and currently pending before the court.

Assertio Holdings, Inc. has 68 institutional owners and shareholders, holding a total of 19,965,538 shares. Major institutional owners include Nantahala Capital Management, LLC, Renaissance Technologies Llc, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), BlackRock, Inc., Vanguard Extended Market Index Fund Investor Shares (VEXMX), Geode Capital Management, Llc, Millennium Management Llc, Morgan Stanley, Two Sigma Advisers, Lp, Gsa Capital Partners Llp, Vanguard Index Funds, Fidelity Concord Street Trust, Perritt Capital Management Inc., Tiaa Cref Funds, Stifel Asset Management Corp., and State Street Global Advisors, Inc. Major individual insider transactions in the past year include buys by Mason Heather L. and O'Grady Brendan P.